PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
 
Curr HIV Res. 2012 June; 10(4): 327–333.
Published online 2012 June. doi:  10.2174/157016212800792513
PMCID: PMC3412205

HIV-1 Vpu Interference with Innate Cell-mediated Immune Mechanisms

Abstract

The HIV-1 accessory protein Vpu is emerging as a viral factor with a range of activities devoted to counteracting host innate immunity. Here, we review recent findings concerning the role of Vpu in hampering activation of cellular immune responses mediated by CD1d-restricted invariant natural killer T (iNKT) cells and natural killer (NK) cells. The two key findings are that Vpu interferes with CD1d expression and antigen presentation, and also with expression of the NK cell activation ligand NK-T and B cell antigen (NTB-A). Both these activities are mechanistically distinct from CD4 and Tetherin (BST-2) down-modulation. We summarize the mechanistic insights gained into Vpu interference with CD1d and NTB-A, as well as important challenges going forward, and discuss these mechanisms in the context of the role that iNKT and NK cells play in HIV-1 immunity and immunopathogenesis.

Keywords: HIV-1, iNKT cells, CD1d, Vpu, NK cells, immune evasion, NTB-A, Nef, Vpr.

INTRODUCTION

Cellular immunity is important for host defense against viral infections. Immune cells with innate characteristics have the capacity to respond rapidly without the need for an extensive priming phase, and such cells may therefore be particularly important in controlling viral replication during the first days of an infection. This group of cells includes invariant CD1d-restricted natural killer T (iNKT) and natural killer (NK) cells. iNKT cells are characterized by a semi-invariant T cell receptor (TCR) that uses the TCR α-chain segments Vα24 and Jα18 preferentially paired with the variable β-chain Vβ11 segment [1]. They have a surface phenotype reminiscent of effector memory T cells [2, 3], and can be subdivided into CD4+ and CD4- subsets with distinct functional profiles [4, 5]. iNKT cells respond rapidly to two distinct types of stimuli. First, they can recognize foreign glycolipid antigens presented by CD1d molecules expressed by antigen presenting cells such as dendritic cells (DCs), monocytes and B cells [6, 7]. This mode of activation has been observed with antigens from certain species of bacteria, such as Sphingomonas [8, 9], and Borrelia burgdorferi [10]. Secondly, iNKT cells can be activated in the absence of cognate CD1d-presented antigen through TCR recognition of endogenous lipids in the context of inflammatory cytokines such as IL-12 and IL-18 [11, 12]. The endogenous antigens recognized in this way have long remained elusive, but very recently β-D-glucopyranosylceramide (β-GlcCer) was identified as one such antigen [13]. β-GlcCer was found to accumulate in response to infection as well as TLR agonists, suggesting that this type of recognition may be relevant for several pathogens including viruses.

NK cells mediate their effector function through cytolysis and production of cytokines and chemokines, and these activities are regulated by a vast array of activating and inhibitory receptors [14, 15]. One important activating receptor is natural-killer group 2 member D (NKG2D) which mediates activation upon engagement of stress-induced MHC class I-related chain A and B (MICA/B) and members of the UL16-binding protein (ULBP) family [16, 17]. Another activating NK cell receptor is DNAX accessory molecule-1 (DNAM-1), which recognizes both the poliovirus receptor (PVR) (CD155) and Nectin-2 (CD112) [18]. During a viral infection, the activating and inhibitory receptors collectively have the delicate task to allow and facilitate activation of anti-viral effector mechanisms against infected cells, while at the same time limiting collateral damage to uninfected host cells [19]. Convincing evidence for an important role of NK cells in viral infections in humans comes from patients with NK cell defects that have higher susceptibility to certain viruses, including herpes viruses [20-22]. There is also evidence that several viruses modulate expression of ligands for activating and inhibitory NK cell receptors to evade recognition by these cells [22].

In this paper, we briefly review what is currently known about the role of iNKT cells and NK cells in HIV-1 infection with a special focus on the recent findings that the HIV-1 vpu gene-product interferes with expression of the iNKT cell ligand CD1d [23], as well as the homotypic activating NK cell receptor/ligand NTB-A [24].

iNKT CELLS IN HIV-1 INFECTION

In 2002, three groups independently reported that levels of iNKT cells in peripheral blood are severely depressed in HIV-1 infected adults [25, 26], and children [27] (Fig. 11). This was subsequently confirmed by others [28], and similar findings were made in non-human primate models of SIV infection [29]. The loss of iNKT cells appears to be rapid in many patients, and this may be at least partly due to high levels of CCR5 expression making them preferential targets for HIV-1 (Fig. 11) [26, 27, 30]. Somewhat conflicting data exist regarding the ability of antiretroviral treatment (ART) to rescue quantitative and qualitative aspects of the iNKT cell compartment, and the efficacy of ART in this context may depend on timing of initiation of treatment [28, 31-34]. Some patients retain almost normal numbers of iNKT cells throughout untreated chronic HIV-1 infection, but those cells express an exhausted phenotype with elevated PD-1 expression [32, 35]. The mechanisms by which iNKT cells respond to HIV-1 infection are incompletely known, although iNKT cell supernatants have been shown to inhibit HIV replication in vitro [28]. Solid, albeit indirect, evidence for an important role of iNKT cells in immune defense against HIV-1 comes from the recent observations that the virus carries several mechanisms for down-regulation of the iNKT cell ligand CD1d (Fig. 11) [23, 36, 37].

Fig. (1)
HIV-1 impacts iNKT cells at three levels. Figure illustrates the three known ways that HIV-1 infection interferes with the function of iNKT cells. iNKT cells are susceptible to direct HIV-1 infection. The residual iNKT cells that persist in chronic infection ...

INTERFERENCE WITH CD1d-MEDIATED ANTIGEN PRESENTATION BY HIV-1 VPU AND NEF

Over the last decade is has become clear that recognition of lipid antigens by the immune system plays an important role in the host defense to infectious diseases [38]. In humans, endogenous and exogenous lipid-antigens are presented to T cells by four different CD1 molecules; CD1a, CD1b and CD1c (group I), and CD1d (group II) [39, 40]. These four types of CD1 molecules have distinct cellular expression profiles as well as different sub-cellular distributions, indicating a sophisticated system to survey the presence of lipid antigens [39, 40]. Expression of group I CD1 molecules is mainly confined to professional antigen presenting cells (APCs) such as DCs and Langerhans cells, while CD1d is also expressed in monocytes, macrophages, B cell subsets, and some non-hematopoietic cells [7]. Noteworthy, CD1d is absent from the surface of naïve T cells but can be expressed upon T cell activation [41]. Thus, CD1 molecules have an expression pattern that largely overlaps with the host cell range of HIV-1.

In recent years it has become evident, that the two accessory HIV-1 proteins Nef and Vpu inhibit the surface expression of CD1d in a concerted action by intervening with the intracellular trafficking of CD1d. Under normal conditions, CD1d molecules, after initial trafficking to the cell surface, constitutively recycle between the surface and endosomal compartments to survey the endocytic system for the presence of lipid antigens [42]. Nef tends to retain CD1d in the trans-Golgi network and increases its rate of internalization from the cell surface [36]. Vpu on the other hand decreases the recycling of CD1d from endosomal compartments to the cell surface, and co-localization of Vpu and CD1d in early endosome antigen 1 (EEA-1) positive structures indicates retention of CD1d in the early endosome [23]. Putting these observations together, we suggest a model where Nef and Vpu in a synergistic fashion achieve the efficient inhibition of CD1d cell surface expression in productively infected DCs (Fig. 22). This model is supported by the finding that virus mutants lacking the expression of either Nef or Vpu still partially down-regulate CD1d whereas a Nef/Vpu double-defective virus completely lacks this activity [23]. Whereas the detailed molecular mechanisms and structural requirements remain to be elucidated, physical interaction between CD1d and Nef as well as CD1d and Vpu has been detected [23, 37]. It is, however, unclear if the observed interactions are of direct nature or if other cellular co-factors are involved in complex formation and down-regulation. In addition to the effects of Nef and Vpu, a single report suggested that adding soluble HIV gp120 protein to U937 cells reduced surface CD1d expression on these cells [43]. The potential mechanisms involved and relationship to the Vpu- and Nef-mediated effects on the CD1d antigen presentation pathway remains to be determined.

Fig. (2)
HIV-1 Vpu and Nef interfere with CD1d-mediated antigen presentation. A) The normal AP-2 dependent trafficking of CD1d through early and late endosomal compartments for antigen loading and presentation to iNKT cells. B) In HIV-1 infected cells this process ...

CD1d internalization from the cell surface requires interaction of a tyrosine-based motif in its cytoplasmic tail with adaptor protein complex-2 (AP-2) [42]. Mutation of the known AP-2 binding sites in Nef strongly affected CD1d down-regulation, indicating that Nef enhances CD1d internalization by subverting the regular AP-2 mediated trafficking of CD1d [36, 44]. Although Vpu contains three potential AP-binding motifs in its cytoplasmic domain, Vpu interaction with AP-2 or other adaptor protein complexes has so far not been demonstrated [45], making involvement of AP-2 in Vpu-mediated inhibition of CD1d expression unlikely. Down-regulation of CD4 and tetherin involves association of Vpu with the cellular co-factor β-TrCP to mediate ubiquitination and proteasomal degradation, and phosphorylation of Vpu at serine residues 52 and 56 may be important in this process [45]. The contributions of proteasomal and lysosomal degradation in down-regulation of tetherin from the cell surface are, however, controversially discussed [46, 47]. Moreover, enhancement of virus particle release by Vpu may occur in the complete absence of tetherin degradation suggesting that the two processes are not related [48]. However, because CD1d down-regulation from the cell surface does not require Vpu phosphorylation (our unpublished observation), involvement of β-TrCP-mediated ubiquitination and proteasomal degradation is unlikely to be involved in this process. These results collectively prompt the search for cellular co-factors binding Vpu and contributing to the Vpu-mediated retention of CD1d in early endosomal compartments.

The consequences of CD1d down-regulation have been assessed in different experimental systems and comprise early and late events of iNKT cell activation. HIV-1 infected DCs, as well as Vpu-transfected cell lines, loaded with the model lipid antigen α-galactosylceramide have a significantly reduced capacity to induce the formation of an immunological synapse with iNKT cells [23]. Likewise, the activation of iNKT cells is reduced when either Nef- or Vpu-transfected cell lines or HIV-1 infected DCs are used for stimulation, demonstrating the potency of viral interference with CD1d expression [23, 36, 37]. Reversion of the phenotype by deleting functional expression of Nef and Vpu fully restores the capacity of DCs to induce iNKT cell activation, indicating that HIV-1 infected DCs are not unable per se to activate iNKT cells [23].

Interference of HIV-1 with the group I CD1 system and T cell responses to antigens presented by these CD1 molecules has not been much studied. The effect of HIV-1 on group I CD1 proteins was described in only a single report, where CD1a down-regulation from the cell surface was observed in DCs infected with recombinant HIV-1 pseudotyped with VSV-G [49]. In that study, expression of CD1b and CD1c was unaffected, and even down-regulation of CD1d was not observed. Mechanistically, down-regulation of CD1a appeared to be linked to the redistribution of this molecule from the cell surface to LAMP-1 positive compartments, an effect mediated by the Nef protein. The biological consequences of HIV-1 interference with CD1a expression remain unclear and need further investigation.

NK CELLS IN HIV-1 INFECTION

NK cells play a very important and multifaceted role in control of HIV-1 infection and replication [50]. NK cells can fight HIV-1 via direct cytolysis of infected cells [51-53], and production of chemokines and cytokines that directly or indirectly inhibit viral entry and replication [54, 55]. In addition, HIV-binding antibodies allow NK cells to mediate antibody-dependent cellular cytotoxicity (ADCC), which probably also contributes to control of virus [56, 57].

NK cell activity is balanced by signals from activating and inhibitory receptors [14, 15]. Killer-cell immunoglobulin-like receptors (KIRs) and their HLA class ligands are of particular interest in the HIV field, since the observation that individuals expressing the activating receptor KIR3DS1 together with certain HLA-Bw4 alleles show slower progression to AIDS than people lacking either one or both of these receptors [58]. In addition, individuals carrying some alleles of the inhibitory KIR3DL1 receptor also display slower HIV disease progression [59]. The importance of the KIR3DL1/DS1 interaction with HLA-Bw4 has been substantiated by the observation that KIR3DS1+ NK cells are more effective in killing HIV-infected HLA-Bw4+ target cells [60]. Furthermore, KIR3DL1/DS1+ NK cells expand in infected subjects carrying HLA-Bw4 [61, 62], and this NK cell expansion correlates with viral load in chronic infection [62].

Engagement of the NK cell compartment in the response to HIV-1 furthermore results in global changes in receptor expression levels and subset distribution [63, 64]. These changes include the relative subset redistribution with fewer CD56dim NK cells and expansion of an aberrant CD56 negative NK cell subset. The detailed mechanisms underlying these changes in receptor expression and subset composition of NK cells still remain largely unknown.

VPU INTERFERENCE WITH NK CELL CYTOLYSIS

With the mounting evidence that NK cells have an important role in the control of HIV-1 infection, one may speculate that the virus should have evolved means to evade NK cell recognition and killing of infected cells. This indeed seems to be the case. It was recently discovered that the NK-T and B cell antigen (NTB-A) is down-regulated from the surface of HIV-1 infected cells [65], in a Vpu-dependent manner [24]. NTB-A is a member of the signaling lymphocytic activation molecule (SLAM) family of receptors [66]. It is expressed on all lymphocytes and acts in a homotypic manner as a co-activating receptor in NK cells [24]. Notably, NTB-A triggering is necessary to induce efficient lysis of target cells upon engagement of the activating receptor NKG2D, and Shah et al. were able to show that down-regulation of NTB-A from the surface of HIV-1 infected cells contributes to the relatively poor NK cell cytolytic activity against such cells (Fig. 33) [24]. Similar to Vpu-mediated down-regulation of CD1d, NTB-A down-regulation does not involve β-TrCP recruitment and subsequent degradation of the protein, nor the enhanced internalization from the cell surface. Interestingly, Vpu mediates its effect on NTB-A via its transmembrane region, and leads to accumulation of the protein in an as of yet not described intracellular compartment.

Fig. (3)
Vpu, Nef and Vpr modulate expression of NK cell ligands on the surface of HIV-1 infected cells. Cell surface ligands of NK cell receptors are modulated by HIV-1 accessory proteins Nef, Vpr and Vpu resulting in the down-regulation of HLA-A and -B molecules, up-regulation ...

HIV-1 Nef is known to inhibit expression of HLA-A and -B class I molecules [67], and the vpr gene-product induces an increased expression of some activating NKG2D ligands (Fig. 33) [68-70]. These changes would be expected to make cells tasty targets for NK cell killing. Vpu-mediated interference with NTB-A expression may thus be very important for HIV-1 to evade elimination by NK cells. Furthermore, it was recently observed that Nef and Vpu together act to down-regulate the DNAM-1 ligand PVR from the surface of infected cells [71] (Fig. 33). Nef appears to mediate this effect on PVR by a mechanism similar to that used to down-regulate MHC class I molecules, whereas the mechanism underlying Vpu’s effects on PVR is unknown [71].

Yet another layer of complexity comes from the observation that NKG2D functions as an activating and co-activating receptor in T cells, including iNKT cells [72]. Vpr-induced expression of ULBPs may thus to some extent counteract the activities by Vpu to inhibit activation of both NK cells and iNKT cells. When viewed together with the effects on tetherin and CD1d, the findings concerning down-regulation of ligands for activating NK cell receptors indicate that Vpu may be a critical factor for HIV-1 evasion from innate immune mechanisms [73].

FUTURE PERSPECTIVES

Significant effort has been put into investigating the capacity of Vpu proteins derived from the different HIV-1 groups to interfere with surface expression and function of CD4 and Tetherin. Whereas the Vpu proteins of pandemic group M viruses are able to induce both CD4 degradation and antagonize Tetherin, HIV-1 group N, O and P Vpu proteins perform only one of these functions [74, 75]. The non-pandemic groups of viruses are geographically restricted to West-central Africa, and acquisition of a functionally fully competent Vpu may have contributed to the global success of HIV-1 group M viruses [76]. In this context it will be important to investigate if the capacity to inhibit expression of CD1d and NTB-A is conserved among Vpu proteins derived from the different HIV-1 groups.

The question arises why HIV-1 with its limited genome, in the face of severe selection pressures, maintains the ability to interfere with the lipid antigen presenting molecule CD1d. To our knowledge, neither HIV-specific T cells restricted by CD1 molecules nor HIV-derived lipid antigens have yet been identified. Furthermore, viruses do not encode lipids, and the lipid envelope of HIV is derived from host cell membranes. The need to interfere with CD1-mediated antigen presentation is therefore not self-evident. A possible scenario is that iNKT cell recognition of infected cells is independent of foreign lipid antigen. Cytokines produced by a virus infected or exposed cell in combination with the recognition of endogenous lipid antigens presented by CD1d may be sufficient for iNKT cell activation. It is also possible that an altered lipid metabolism in HIV infected cells may generate an altered endogenous lipid antigen content in CD1 molecules. Furthermore, the recent discovery that CD1a and CD1c are able to present lipid-modified peptides opens up the possibility that virally derived lipopeptides may be presented by CD1 molecules [77, 78]. Future studies may reveal if the myristoylated HIV-1 proteins p17 and Nef give rise to CD1-presented lipopeptide structures enabling T cells to recognize HIV-1 infected cells.

Nef is expressed early, whereas Vpu is expressed late in the HIV-1 life cycle [79]. The effects that these viral proteins have on CD1d, NTB-A, MHC class I, and PVR may therefore vary over the life span of a productively infected cell. Detailed studies of the expression of these viral factors as well as their target host proteins over time in DCs and CD4 T cells may give important insight into the complexity of Vpu- and Nef-mediated evasion from innate cell-mediated immunity.

Elucidation of the fine mechanistic detail of Vpu-mediated inhibition of CD1d and NTB-A expression will be important for the basic understanding of these apparent immune evasion mechanisms. Furthermore, this level of understanding may allow rational design of a novel class of anti-viral treatments. We speculate that pharmaceutical interference with these functions of Vpu might help improve the contribution of innate immunity to control of viral replication.

ACKNOWLEDGEMENTS

This work was supported by the Swedish Research Council, the Swedish Cancer Foundation, the Swedish Physicians Against AIDS Foundation, Karolinska Institutet, Stockholm County Council, and the US National Institutes of Health grant AI52731.

CONFLICT OF INTEREST

Declared none.

REFERENCES

1. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol. 2007;25:297–336. [PubMed]
2. van Der Vliet HJ, Nishi N, de Gruijl TD, von Blomberg BM, van Den Eertwegh AJ, Pinedo HM, et al. Human natural killer T cells acquire a memory-activated phenotype before birth. Blood. 2000; 95(7):2440–2. [PubMed]
3. Sandberg JK, Bhardwaj N, Nixon DF. Dominant effector memory characteristics, capacity for dynamic adaptive expansion, and sex bias in the innate Valpha24 NKT cell compartment. Eur J Immunol . 2003;33(3):588–96. [PubMed]
4. Gumperz JE, Miyake S, Yamamura T, Brenner MB. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med. 2002;195(5):625–36. [PMC free article] [PubMed]
5. Lee PT, Benlagha K, Teyton L, Bendelac A. Distinct functional lineages of human V(alpha)24 natural killer T cells. J Exp Med . 2002;195(5):637–41. [PMC free article] [PubMed]
6. Godfrey DI, Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest. 2004;114(10):1379–88. [PMC free article] [PubMed]
7. Dougan SK, Kaser A, Blumberg RS. CD1 expression on antigen-presenting cells. Curr Top Microbiol Immunol. 2007;314:113–41. [PubMed]
8. Kinjo Y, Wu D, Kim G, et al. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature. 2005; 434(7032):520–5. [PubMed]
9. Mattner J, Debord KL, Ismail N, et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature. 2005;434(7032):525–9. [PubMed]
10. Kinjo Y, Tupin E, Wu D, et al. Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat Immunol . 2006;7(9):978–86. [PubMed]
11. Brigl M, Bry L, Kent SC, Gumperz JE, Brenner MB. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat Immunol. 2003;4(12):1230–7. [PubMed]
12. Lind SM, Kuylenstierna C, Moll M, et al. IL-18 skews the invariant NKT-cell population via autoreactive activation in atopic eczema. Eur J Immunol. 2009;39(8):2293–301. [PubMed]
13. Brennan PJ, Tatituri RV, Brigl M, et al. Invariant natural killer T cells recognize lipid self antigen induced by microbial danger signals. Nat Immunol. 2011;12(12):1202–11. [PMC free article] [PubMed]
14. Bryceson YT, March ME, Ljunggren HG, Long EO. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev. 2006;214:73–91. [PubMed]
15. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008;9(5):495–502. [PMC free article] [PubMed]
16. Cosman D, Mullberg J, Sutherland CL, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity . 2001;14(2):123–33. [PubMed]
17. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress- inducible MICA. Science. 1999; 285(5428):727–9. [PubMed]
18. Shibuya A, Campbell D, Hannum C, et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity. 1996;4(6):573–81. [PubMed]
19. Vidal SM, Khakoo SI, Biron CA. Natural Killer Cell Responses during Viral Infections: Flexibility and Conditioning of Innate Immunity by Experience. Curr Opin Virol. 2011;1(6):497–512. [PMC free article] [PubMed]
20. Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med. 1989; 320(26):1731–5. [PubMed]
21. Orange JS. Human natural killer cell deficiencies. Curr Opin Allergy Clin Immunol. 2006;6(6):399–409. [PubMed]
22. Lanier LL. Evolutionary struggles between NK cells and viruses. Nat Rev Immunol. 2008;8(4):259–68. [PMC free article] [PubMed]
23. Moll M, Andersson SK, Smed-Sorensen A, Sandberg JK. Inhibition of lipid antigen presentation in dendritic cells by HIV-1 Vpu interference with CD1d recycling from endosomal compartments. Blood. 2010;116(11):1876–84. [PubMed]
24. Shah AH, Sowrirajan B, Davis ZB, et al. Degranulation of natural killer cells following interaction with HIV-1-infected cells is hindered by downmodulation of NTB-A by Vpu. Cell Host Microbe. 2010;8(5):397–409. [PMC free article] [PubMed]
25. van der Vliet HJ, von Blomberg BM, Hazenberg MD, et al. Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection. J Immunol. 2002;168(3):1490–5. [PubMed]
26. Motsinger A, Haas DW, Stanic AK, Van Kaer L, Joyce S, Unutmaz D. CD1d-restricted human natural killer T cells are highly susceptible to human immunodeficiency virus 1 infection. J Exp Med. 2002;195(7):869–79. [PMC free article] [PubMed]
27. Sandberg JK, Fast NM, Palacios EH, Fennelly G, Dobroszycki J, Palumbo P, et al. Selective loss of innate CD4(+) V alpha 24 natural killer T cells in human immunodeficiency virus infection. J Virol. 2002;76(15):7528–34. [PMC free article] [PubMed]
28. Vasan S, Poles MA, Horowitz A, Siladji EE, Markowitz M, Tsuji M. Function of NKT cells, potential anti-HIV effector cells, are improved by beginning HAART during acute HIV-1 infection. Int Immunol. 2007;19(8):943–51. [PubMed]
29. Fernandez CS, Chan AC, Kyparissoudis K, De Rose R, Godfrey DI, Kent SJ. Peripheral NKT cells in simian immunodeficiency virus-infected macaques. J Virol. 2009;83(4):1617–24. [PMC free article] [PubMed]
30. Fleuridor R, Wilson B, Hou R, Landay A, Kessler H, Al-Harthi L. CD1d-restricted natural killer T cells are potent targets for human immunodeficiency virus infection. Immunology. 2003;108(1):3–9. [PubMed]
31. van der Vliet HJ, van Vonderen MG, Molling JW, et al. Cutting edge: Rapid recovery of NKT cells upon institution of highly active antiretroviral therapy for HIV-1 infection. J Immunol. 2006;177(9): 5775–8. [PubMed]
32. Moll M, Kuylenstierna C, Gonzalez VD, et al. Severe functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells retained during chronic HIV-1 infection. Eur J Immunol. 2009; 39(3):902–11. [PMC free article] [PubMed]
33. Moll M, Snyder-Cappione J, Spotts G, Hecht FM, Sandberg JK, Nixon DF. Expansion of CD1d-restricted NKT cells in patients with primary HIV-1 infection treated with interleukin-2. Blood . 2006;107(8):3081–3. [PubMed]
34. Kuylenstierna C, Snyder-Cappione JE, Loo CP, et al. NK cells and CD1d-restricted NKT cells respond in different ways with divergent kinetics to IL-2 treatment in primary HIV-1 infection. Scand J Immunol. 2011;73(2):141–6. [PMC free article] [PubMed]
35. Snyder-Cappione JE, Loo CP, Carvalho KI, et al. Lower cytokine secretion ex vivo by natural killer T cells in HIV-infected individuals is associated with higher CD161 expression. AIDS . 2009;23(15):1965–70. [PubMed]
36. Chen N, McCarthy C, Drakesmith H, et al. HIV-1 down-regulates the expression of CD1d via Nef. Eur J Immunol. 2006;36(2):278–86. [PubMed]
37. Cho S, Knox KS, Kohli LM, et al. Impaired cell surface expression of human CD1d by the formation of an HIV-1 Nef/CD1d complex. Virology. 2005;337(2):242–52. [PubMed]
38. Behar SM, Porcelli SA. CD1-restricted T cells in host defense to infectious diseases. Curr Top Microbiol Immunol. 2007;314:215–50. [PubMed]
39. Moody DB. The surprising diversity of lipid antigens for CD1- restricted T cells. Adv Immunol. 2006;89:87–139. [PubMed]
40. Brigl M, Brenner MB. CD1: antigen presentation and T cell function. Annu Rev Immunol. 2004;22:817–90. [PubMed]
41. Salamone MC, Rabinovich GA, Mendiguren AK, Salamone GV, Fainboim L. Activation-induced expression of CD1d antigen on mature T cells. J Leukoc Biol. 2001;69(2):207–14. [PubMed]
42. Moody DB, Porcelli SA. Intracellular pathways of CD1 antigen presentation. Nat Rev Immunol. 2003;3(1):11–22. [PubMed]
43. Hage CA, Kohli LL, Cho S, Brutkiewicz RR, Twigg HL, 3rd, Knox KS. Human immunodeficiency virus gp120 downregulates CD1d cell surface expression. Immunol Lett. 2005;98(1):131–5. [PubMed]
44. Chaudhuri R, Lindwasser OW, Smith WJ, Hurley JH, Bonifacino JS. Downregulation of CD4 by human immunodeficiency virus type 1 Nef is dependent on clathrin and involves direct interaction of Nef with the AP2 clathrin adaptor. J Virol. 2007;81(8):3877–90. [PMC free article] [PubMed]
45. Tokarev A, Guatelli J. Misdirection of membrane trafficking by HIV-1 Vpu and Nef: Keys to viral virulence and persistence. Cell Logist. 2011;1(3):90–102. [PMC free article] [PubMed]
46. Mangeat B, Gers-Huber G, Lehmann M, Zufferey M, Luban J, Piguet V. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog. 2009;5(9):e1000574. [PMC free article] [PubMed]
47. Dube M, Roy BB, Guiot-Guillain P, et al. Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. PLoS Pathog. 2010;6(4):e1000856. [PMC free article] [PubMed]
48. Goffinet C, Homann S, Ambiel I, et al. Antagonism of CD317 restriction of human immunodeficiency virus type 1 (HIV-1) particle release and depletion of CD317 are separable activities of HIV-1 Vpu. J Virol. 2010;84(8):4089–94. [PMC free article] [PubMed]
49. Shinya E, Owaki A, Shimizu M, et al. Endogenously expressed HIV-1 nef down-regulates antigen-presenting molecules, not only class I MHC but also CD1a, in immature dendritic cells. Virology . 2004;326(1):79–89. [PubMed]
50. Altfeld M, Fadda L, Frleta D, Bhardwaj N. DCs and NK cells: critical effectors in the immune response to HIV-1. Nat Rev Immunol. 2011;11(3):176–86. [PMC free article] [PubMed]
51. Bandyopadhyay S, Ziegner U, Campbell DE, Miller DS, Hoxie JA, Starr SE. Natural killer cell-mediated lysis of T cell lines chronically infected with HIV-1. Clin Exp Immunol. 1990;79(3): 430–5. [PubMed]
52. Bonaparte MI, Barker E. Killing of human immunodeficiency virus-infected primary T-cell blasts by autologous natural killer cells is dependent on the ability of the virus to alter the expression of major histocompatibility complex class I molecules. Blood . 2004;104(7):2087–94. [PubMed]
53. Fogli M, Mavilio D, Brunetta E, et al. Lysis of endogenously infected CD4+ T cell blasts by rIL-2 activated autologous natural killer cells from HIV-infected viremic individuals. PLoS Pathog . 2008;4(7):e1000101. [PMC free article] [PubMed]
54. Fehniger TA, Herbein G, Yu H, et al. Natural killer cells from HIV-1+ patients produce C-C chemokines and inhibit HIV-1 infection. J Immunol. 1998;161(11):6433–8. [PubMed]
55. Oliva A, Kinter AL, Vaccarezza M, et al. Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. J Clin Invest. 1998;102(1):223–31. [PMC free article] [PubMed]
56. Baum LL, Cassutt KJ, Knigge K, et al. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol. 1996;157(5):2168–73. [PubMed]
57. Lambotte O, Ferrari G, Moog C, et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS. 2009;23(8):897–906. [PubMed]
58. Martin MP, Gao X, Lee JH, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet . 2002;31(4):429–34. [PubMed]
59. Martin MP, Qi Y, Gao X, et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet. 2007;39(6):733–40. [PubMed]
60. Alter G, Martin MP, Teigen N, et al. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med. 2007;204(12):3027–36. [PMC free article] [PubMed]
61. Alter G, Rihn S, Walter K, et al. HLA class I subtype-dependent expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute human immunodeficiency virus type 1 infection. J Virol. 2009; 83(13):6798–805. [PMC free article] [PubMed]
62. Eller MA, Koehler RN, Kijak GH, et al. Human immunodeficiency virus type 1 infection is associated with increased NK cell polyfunctionality and higher levels of KIR3DL1+ NK cells in ugandans carrying the HLA-B Bw4 motif. J Virol. 2011;85(10): 4802–11. [PMC free article] [PubMed]
63. Bjorkstrom NK, Ljunggren HG, Sandberg JK. CD56 negative NK cells: Origin, function, and role in chronic viral disease. Trends Immunol. 2010;31:401–6. [PubMed]
64. Brunetta E, Hudspeth KL, Mavilio D. Pathologic natural killer cell subset redistribution in HIV-1 infection: new insights in pathophysiology and clinical outcomes. J Leukoc Biol. 2010;88(6): 1119–30. [PubMed]
65. Ward J, Bonaparte M, Sacks J, et al. HIV modulates the expression of ligands important in triggering natural killer cell cytotoxic responses on infected primary T-cell blasts. Blood. 2007;110(4): 1207–14. [PubMed]
66. Cannons JL, Tangye SG, Schwartzberg PL. SLAM family receptors and SAP adaptors in immunity. Annu Rev Immunol . 2011;29:665–705. [PubMed]
67. Cohen GB, Gandhi RT, Davis DM, et al. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity. 1999;10(6):661–71. [PubMed]
68. Richard J, Sindhu S, Pham TN, Belzile JP, Cohen EA. HIV-1 Vpr up-regulates expression of ligands for the activating NKG2D receptor and promotes NK cell-mediated killing. Blood. 2010; 115(7):1354–63. [PubMed]
69. Ward J, Davis Z, DeHart J, et al. HIV-1 Vpr triggers natural killer cell-mediated lysis of infected cells through activation of the ATR-mediated DNA damage response. PLoS Pathog. 2009;5(10): e1000613. [PMC free article] [PubMed]
70. Pham TN, Richard J, Gerard FC, Power C, Cohen EA. Modulation of NKG2D-mediated cytotoxic functions of natural killer cells by viral protein R from HIV-1 primary isolates. J Virol. 2011;85(23): 12254–61. [PMC free article] [PubMed]
71. Matusali G, Potesta M, Santoni A, Cerboni C, Doria M. The Human Immunodeficiency Virus Type 1 Nef and Vpu Proteins Down-regulate The Natural Killer Cell Activating Ligand PVR. J Virol. 2012. [PMC free article] [PubMed]
72. Kuylenstierna C, Bjorkstrom NK, Andersson SK, et al. NKG2D performs two functions in invariant NKT cells: direct TCR-independent activation of NK-like cytolysis and co-stimulation of activation by CD1d. Eur J Immunol. 2011;41(7):1913–23. [PMC free article] [PubMed]
73. Richard J, Cohen EA. HIV-1 Vpu disarms natural killer cells. Cell Host Microbe. 2010;8(5):389–91. [PubMed]
74. Dube M, Bego MG, Paquay C, Cohen EA. Modulation of HIV-1-host interaction: role of the Vpu accessory protein. Retrovirology . 2010;7:114. [PMC free article] [PubMed]
75. Sauter D, Hue S, Petit SJ, et al. HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef. Retrovirology . 2011;8(1):103. [PMC free article] [PubMed]
76. Sauter D, Schindler M, Specht A, et al. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe. 2009;6(5):409–21. [PMC free article] [PubMed]
77. Moody DB, Young DC, Cheng TY, et al. T cell activation by lipopeptide antigens. Science. 2004;303(5657):527–31. [PubMed]
78. Van Rhijn I, Young DC, De Jong A, et al. CD1c bypasses lysosomes to present a lipopeptide antigen with 12 amino acids. J Exp Med. 2009;206(6):1409–22. [PMC free article] [PubMed]
79. Kirchhoff F. Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. Cell Host Microbe . 2010;8(1):55–67. [PubMed]

Articles from Bentham Open Access are provided here courtesy of Bentham Science Publishers